# C. R. Bard clinical trials: 117 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 117 trials with C. R. Bard as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by C. R. Bard: 117 rows for $5.85, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/c-r-bard

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 117
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 117, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 4, 2026 | NCT07744945 | Evaluation of Male and Female External Catheters for Urine Output Monitoring in the ICU | C. R. Bard | Observational | Enrolling by invitation | Urine Output, ICU Patients | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744945) |
| December 15, 2025 | NCT07282860 | An Evaluation of the PureWick™ Male External Catheter Versus an Established Comparator Overnight in the Home Setting for Incontinence in... | C. R. Bard | Not applicable | Completed | Urinary Incontinence | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282860) |
| June 12, 2025 | NCT07016698 | Real-World Registry of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry) | C. R. Bard | Not applicable | Recruiting | Peripheral Arterial Disease(PAD) | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07016698) |
| April 18, 2025 | NCT06934486 | Observational Study of TissuePatch SF in Prevention of Air Leaks Following Lung Resection | C. R. Bard | Observational | Not yet recruiting | Post-operative Air Leaks | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06934486) |
| February 27, 2025 | NCT06850259 | This Study Will Collect Clinical and Patient Reported Satisfaction Data From Males Requiring Urine Output Management Overnight in the Home... | C. R. Bard | Not applicable | Completed | Urinary Incontinence | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06850259) |
| November 1, 2024 | NCT06669806 | Effectiveness and Safety of TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Portal Hypertension | C. R. Bard | Not applicable | Recruiting | Portal Hypertension Related to Cirrhosis, Ascites Hepatic, Variceal Bleeding | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06669806) |
| October 30, 2024 | NCT06666426 | This Study Will Collect Clinical and Patient Reported Experience Data From Participants Requiring Urine Output Management Overnight in the... | C. R. Bard | Not applicable | Completed | Adult Nocturnal Enuresis, Urinary Incontinence (UI) | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06666426) |
| October 8, 2024 | NCT06631313 | PureWick™ Adolescent Study | C. R. Bard | Not applicable | Completed | Healthy Volunteers, Adolescent | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06631313) |
| July 21, 2023 | NCT05955560 | Male External Catheters' Comparison of Comfort and Efficacy | C. R. Bard | Not applicable | Completed | Non-invasive Urine Output Management | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05955560) |
| July 14, 2023 | NCT05945329 | Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation | C. R. Bard | Not applicable | Recruiting | Capsular Contracture Associated With Breast Implant, Capsular Contracture Grade III, Capsular Contracture Grade IV | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05945329) |
| February 3, 2023 | NCT05711316 | The BD Liverty™ TIPS Stent Graft Study | C. R. Bard | Not applicable | Active not recruiting | Portal Hypertension, TIPS | 177 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05711316) |
| February 2, 2023 | NCT05710718 | PureWick™ France and U.S. At-Home Pilot Study | C. R. Bard | Not applicable | Completed | Nocturnal Enuresis | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05710718) |
| September 27, 2022 | NCT05556681 | Study of BD Sirolimus Drug Coated Catheter for Treatment of Femoropopliteal Arteries | C. R. Bard | Not applicable | Completed | Peripheral Arterial Disease, Peripheral Artery Disease, Stenosis Artery | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05556681) |
| August 17, 2022 | NCT05504070 | Venclose digiRF System Post Market Study | C. R. Bard | Not applicable | Active not recruiting | Venous Reflux, Chronic Venous Insufficiency | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05504070) |
| February 8, 2022 | NCT05228132 | The Pristine Post-Market Study | C. R. Bard | Not applicable | Terminated | Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure... | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05228132) |
| February 21, 2021 | NCT04765566 | FLUENCY® PLUS in the Treatment of Peripheral Artery Disease | C. R. Bard | Observational | Completed | Vascular Diseases, Peripheral | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04765566) |
| November 18, 2020 | NCT04634916 | Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System | C. R. Bard | Not applicable | Recruiting | Kidney Disease, End-Stage, End-stage Renal Disease, Arteriovenous Fistula | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04634916) |
| November 12, 2020 | NCT04626427 | The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation | C. R. Bard | Not applicable | Terminated | End Stage Kidney Disease, Chronic Kidney Diseases, Kidney Failure, Kidney Insufficiency, Kidney Disease, Chronic, AV... | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04626427) |
| February 10, 2020 | NCT04261686 | Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft | C. R. Bard | Not applicable | Completed | Arteriovenous Fistula | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04261686) |
| January 28, 2020 | NCT04244370 | Caterpillar™ Arterial Embolization Device Post-Market Study | C. R. Bard | Not applicable | Completed | Embolization, Therapeutic | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04244370) |
| December 12, 2019 | NCT04195854 | STARS-R Registry: Retrospective Analysis of Poly-4-hydroxybutyrate (P4HB) Scaffold Use | C. R. Bard | Observational | Completed | Plastic Surgery, Reconstructive Surgery | 1,183 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04195854) |
| September 16, 2019 | NCT04090320 | CATERPILLAR™ Arterial Embolization Device Study | C. R. Bard | Not applicable | Completed | Embolization, Therapeutic | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04090320) |
| April 11, 2019 | NCT03911700 | Prophylactic Reinforcement of Ventral Abdominal Incisions Trial | C. R. Bard | Not applicable | Active not recruiting | Open Midline Laparotomy | 477 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03911700) |
| October 17, 2018 | NCT03708770 | everlinQ Endovascular Access System Enhancements (EASE) Study | C. R. Bard | Not applicable | Completed | Chronic Kidney Diseases | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03708770) |
| October 17, 2018 | NCT03708562 | everlinQ Endovascular Access Systems Enhancements (EASE-2) Study | C. R. Bard | Not applicable | Completed | Chronic Kidney Diseases | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03708562) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 1/2 | 3 |
| Phase 2 | 3 |
| Phase 3 | 8 |
| Phase 4 | 3 |
| Not applicable | 71 |
| Observational | 26 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 90 |
| Terminated | 16 |
| Active not recruiting | 4 |
| Recruiting | 4 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Peripheral Arterial Disease | 15 |
| Arteriovenous Fistula | 10 |
| Renal Insufficiency, Chronic | 7 |
| Constriction, Pathologic | 7 |
| Kidney Failure, Chronic | 7 |
| Peripheral Vascular Diseases | 6 |
| Hernia | 5 |
| Incisional Hernia | 5 |
| Arterial Occlusive Diseases | 5 |
| Nocturnal Enuresis | 4 |
| Hernia, Ventral | 4 |
| Atrial Fibrillation | 3 |
| Urinary Incontinence | 3 |
| Atherosclerosis | 3 |
| Intermittent Claudication | 3 |
| Nocturia | 2 |
| Aortic Valve Stenosis | 2 |
| Rhabdomyosarcoma, Alveolar | 2 |
| Pleural Effusion, Malignant | 2 |
| Pulmonary Embolism | 2 |
| Neoplasms | 2 |
| Obesity | 2 |
| Weight Loss | 2 |
| Renal Insufficiency | 2 |
| Coronary Stenosis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Graphic design firms in the United States](https://specstream.ai/data/businesses/graphic-design-firms/united-states)
- [Hotel supply companies in the United States](https://specstream.ai/data/businesses/hotel-supply-companies/united-states)
- [Irish pubs in the United States](https://specstream.ai/data/businesses/irish-pubs/united-states)
- [Lighting fixture manufacturers in the United States](https://specstream.ai/data/businesses/lighting-fixture-manufacturers/united-states)
- [Mediterranean restaurants in the United States](https://specstream.ai/data/businesses/mediterranean-restaurants/united-states)
- [Office cleaning companies in the United States](https://specstream.ai/data/businesses/office-cleaning-companies/united-states)
